HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
AALL1131; A Phase 3 Randomized Trial for HR B-ALL with Dasatinib Arm in Ph-like TKI Sensitive Mutations
This study is now recruiting.
The study compares 2 different experimental chemotherapy combinations with the usual chemotherapy combination given during post-Induction therapy. The 3 treatment plans we will be using include: a) therapy containing the usual/standard drugs - Control Arm or, b) therapy containing cyclophosphamide and etoposide- Experimental Arm 1 or, c) therapy containing clofarabine, cyclophosphamide and etoposide – Experimental Arm 2.